Beurs gesloten -
Andere beurzen
|
Variatie 5 dagen | Verschil t.o.v. 1 jan (%) | ||
12,88 USD | +1,42% | -11,78% | -40,86% |
21/03 | VIRIDIAN THERAPEUTICS, INC. : B. Riley ontvangt een koopadvies | ZM |
28/02 | VIRIDIAN THERAPEUTICS, INC. : Wedbush ontvangt een koopadvies | ZM |
Omzet 2024 * | 307K 287K | Omzet 2025 * | 3,11 mln. 2,9 mln. | Marktkapitalisatie | 822 mln. 769 mln. |
---|---|---|---|---|---|
Nettowinst (verlies) 2024 * | -266 mln. -249 mln. | Nettowinst (verlies) 2025 * | -293 mln. -274 mln. | EV/omzet 2024 * | 1.315 x |
Nettoliquiditeiten 2024 * | 418 mln. 391 mln. | Nettoliquiditeiten 2025 * | 587 mln. 549 mln. | EV/omzet 2025 * | 75,6 x |
K/w-verhouding 2024 * |
-2,93
x | K/w-verhouding 2025 * |
-2,96
x | Werknemers | 94 |
Dividendrendement 2024 * |
-
| Dividendrendement 2025 * |
-
| Vrij verhandelbaar | 92,57% |
Recentste transcriptie over Viridian Therapeutics, Inc.
1 dag | +1,42% | ||
1 week | -11,78% | ||
Lopende maand | -26,44% | ||
1 maand | -26,44% | ||
3 maanden | -35,24% | ||
6 maanden | +4,04% | ||
Lopend jaar | -40,86% |
Managers | Titel | Leeftijd | Van |
---|---|---|---|
Chief Executive Officer | 53 | 30-10-23 | |
Seth Harmon
DFI | Director of Finance/CFO | 45 | 01-05-23 |
Thomas Ciulla
CTO | Chief Tech/Sci/R&D Officer | 59 | 01-01-23 |
Besturend | Titel | Leeftijd | Van |
---|---|---|---|
Arlene Morris
BRD | Director/Board Member | 72 | 03-01-18 |
Tomas Kiselak
CHM | Chairman | 38 | 28-10-20 |
Chief Executive Officer | 53 | 30-10-23 |
Naam | Gewicht | Volume | Vaira. 1 jan. | belegger rating |
---|---|---|---|---|
0.06% | 237 M€ | +2,89% | - | |
0.02% | 2 M€ | -.--% | ||
0.01% | 773 M€ | -.--% | - |
Datum | Koers | Variatie | Volume |
---|---|---|---|
26-04-24 | 12,88 | +1,42% | 538 173 |
25-04-24 | 12,7 | -2,53% | 958 729 |
24-04-24 | 13,03 | -8,56% | 771 185 |
23-04-24 | 14,25 | -0,35% | 538 427 |
22-04-24 | 14,3 | -2,05% | 812 430 |
uitgestelde koers Nasdaq, 26 april 2024 om 22:00 uur
Meer koersenHerzieningen van WPA
Vaira. 1 jan. | Kapi. | |
---|---|---|
-40,86% | 822 mln. | |
+1,51% | 42,75 mld. | |
+49,22% | 41,61 mld. | |
+8,57% | 41,34 mld. | |
-12,36% | 26,59 mld. | |
+8,92% | 25,49 mld. | |
-25,13% | 18,12 mld. | |
+29,17% | 12,24 mld. | |
-3,12% | 11,76 mld. | |
+6,35% | 11 mld. |